UY33201A - Compuestos de pirazol como antagonistas de crth2. - Google Patents
Compuestos de pirazol como antagonistas de crth2.Info
- Publication number
- UY33201A UY33201A UY0001033201A UY33201A UY33201A UY 33201 A UY33201 A UY 33201A UY 0001033201 A UY0001033201 A UY 0001033201A UY 33201 A UY33201 A UY 33201A UY 33201 A UY33201 A UY 33201A
- Authority
- UY
- Uruguay
- Prior art keywords
- compounds
- crth2
- anthogonist
- pirazol
- pirazol compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
Abstract
La presente invención se refiere a compuestos de pirazol de fórmula (I) y sales farmacéuticamente a ceptables de los mismos con actividad de CRTH2, en los que W, L1, L2, X, L3 , Y, R1 y R2 son como se define en la memoria descriptiva y en las reivindicaciones, a su uso como medicamentos y a formulaciones farmacéuticas, que contienen dichos compuestos o que contienen una combinación de dichos compuestos con una o más sustancias activas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10151785 | 2010-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY33201A true UY33201A (es) | 2011-08-31 |
Family
ID=42112128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001033201A UY33201A (es) | 2010-01-27 | 2011-01-25 | Compuestos de pirazol como antagonistas de crth2. |
Country Status (37)
Country | Link |
---|---|
US (1) | US8791272B2 (es) |
EP (1) | EP2528901B9 (es) |
JP (1) | JP5658284B2 (es) |
KR (2) | KR101906791B1 (es) |
CN (3) | CN108383789A (es) |
AP (1) | AP3360A (es) |
AR (1) | AR080032A1 (es) |
AU (1) | AU2011209286B2 (es) |
BR (1) | BR112012018695A2 (es) |
CA (1) | CA2788224C (es) |
CL (1) | CL2012001836A1 (es) |
CO (1) | CO6511272A2 (es) |
CY (1) | CY1116641T1 (es) |
DK (1) | DK2528901T3 (es) |
EA (1) | EA022280B1 (es) |
ES (1) | ES2545865T3 (es) |
GE (1) | GEP20146177B (es) |
HK (1) | HK1176062A1 (es) |
HR (1) | HRP20150898T1 (es) |
HU (1) | HUE025318T2 (es) |
IL (1) | IL220208A (es) |
MA (1) | MA33937B1 (es) |
MX (1) | MX353000B (es) |
MY (1) | MY160036A (es) |
NZ (1) | NZ600637A (es) |
PE (1) | PE20121519A1 (es) |
PL (1) | PL2528901T3 (es) |
PT (1) | PT2528901E (es) |
RS (1) | RS54176B1 (es) |
SG (1) | SG182684A1 (es) |
SI (1) | SI2528901T1 (es) |
TN (1) | TN2012000371A1 (es) |
TW (1) | TWI499416B (es) |
UA (1) | UA110025C2 (es) |
UY (1) | UY33201A (es) |
WO (1) | WO2011092140A1 (es) |
ZA (1) | ZA201204335B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108383789A (zh) | 2010-01-27 | 2018-08-10 | 艾克提麦斯医药品有限公司 | 作为crth2拮抗剂的吡唑化合物 |
BR112013012836A2 (pt) | 2010-11-24 | 2019-09-24 | Allergan Inc | moduladores dos receptores s1p" |
TWI527809B (zh) * | 2011-01-24 | 2016-04-01 | 百靈佳殷格翰國際股份有限公司 | 作為crth2拮抗劑之吡唑化合物 |
CN103113303A (zh) * | 2011-11-16 | 2013-05-22 | 山东亨利医药科技有限责任公司 | 作为crth2受体拮抗剂的氮杂环化合物 |
DK2781508T3 (en) | 2011-11-17 | 2019-03-11 | Kbp Biosciences Co Ltd | NITROGEN CONCENTRATED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS |
EP2797893B1 (en) * | 2011-12-27 | 2017-11-22 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
AU2013250726B2 (en) | 2012-04-20 | 2017-01-05 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
WO2014079805A1 (en) * | 2012-11-23 | 2014-05-30 | Boehringer Ingelheim International Gmbh | Pyrazole compounds for treating hairloss |
DK2970138T3 (en) | 2013-03-13 | 2019-03-25 | Canadian Blood Services | PYRAZOLD DERIVATIVES AND THEIR USE THEREOF |
CN103265537B (zh) * | 2013-05-14 | 2015-05-27 | 浙江医药高等专科学校 | 抗肿瘤化合物、其制备方法和用途 |
CN103265535B (zh) * | 2013-05-14 | 2015-06-17 | 浙江医药高等专科学校 | 抗肿瘤化合物、其制备方法和用途 |
MX2017002610A (es) | 2014-08-29 | 2017-10-11 | Tes Pharma S R L | INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA. |
JP7268049B2 (ja) | 2018-03-08 | 2023-05-02 | インサイト・コーポレイション | PI3K-γ阻害剤としてのアミノピラジンジオール化合物 |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
CR20210605A (es) | 2019-06-06 | 2022-01-07 | Basf Se | N-(prid-3-il)carboxamidas fungicidas |
WO2021063735A1 (en) | 2019-10-02 | 2021-04-08 | Basf Se | New bicyclic pyridine derivatives |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4828914B1 (es) * | 1969-04-11 | 1973-09-05 | ||
US4146721A (en) * | 1969-09-12 | 1979-03-27 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pyrazol-4-acetic acid compounds |
BE759032A (fr) * | 1969-11-17 | 1971-04-30 | Takeda Chemical Industries Ltd | Acide 3,5-diphenyl-4-pyrazole acetique ou ses derives 1-substitues ou leurs esters |
US5260322A (en) | 1990-10-08 | 1993-11-09 | Merck & Co., Inc. | Angiotension II antagonists in the treatment of hyperuricemia |
KR100518142B1 (ko) * | 1999-11-10 | 2005-10-04 | 다케다 야쿠힌 고교 가부시키가이샤 | 혈당저하 및 지질혈저하 활성을 갖는 5-원n-헤테로고리형 화합물 |
JP2002348281A (ja) * | 2001-03-23 | 2002-12-04 | Takeda Chem Ind Ltd | 5員複素環アルカン酸誘導体 |
JP2003073377A (ja) * | 2001-06-20 | 2003-03-12 | Takeda Chem Ind Ltd | 5員複素環誘導体 |
CN1321644C (zh) * | 2001-09-25 | 2007-06-20 | 法玛西雅公司 | 制备取代的吡唑的方法 |
AU2003277285B2 (en) * | 2002-10-04 | 2007-12-13 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
ES2257616T3 (es) | 2003-04-25 | 2006-08-01 | Actimis Pharmaceuticals, Inc. | Derivados del acido pirimidinilacetico utiles para el tratamiento de enfermedades mediadas por crth2. |
JP2007509104A (ja) | 2003-10-24 | 2007-04-12 | グラクソ グループ リミテッド | 複素環式化合物 |
GB0525141D0 (en) * | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
GB0525144D0 (en) * | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
EP2040700B1 (en) | 2006-06-06 | 2010-11-24 | Glaxo Group Limited | N- (phenylmethyl) -2- (1h-pyraz0l-4-yl) acetamide derivatives as p2x7 antagonists for the treatment of pain, inflammation and neurodegeneration |
DE602008005582D1 (de) | 2007-05-10 | 2011-04-28 | Glaxo Group Ltd | Pyrazolderivate als p2x7-modulatoren |
NZ584351A (en) | 2007-09-25 | 2012-03-30 | Actimis Pharmaceuticals Inc | 2-S-benzyl substituted pyrimidines as CRTH2 antagonists |
PT2205569E (pt) | 2007-09-25 | 2012-05-25 | Actimis Pharmaceuticals Inc | Alquiltiopirimidinas como antagonistas de crth2 |
GB0719521D0 (en) * | 2007-10-05 | 2007-11-14 | Argenta Discovery Ltd | Compounds |
JP5411927B2 (ja) * | 2008-05-06 | 2014-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ccr1アンタゴニストとしてのピラゾール化合物 |
JP5394487B2 (ja) * | 2008-07-15 | 2014-01-22 | エフ.ホフマン−ラ ロシュ アーゲー | アミノテトラヒドロインダゾロ酢酸 |
CN108383789A (zh) | 2010-01-27 | 2018-08-10 | 艾克提麦斯医药品有限公司 | 作为crth2拮抗剂的吡唑化合物 |
-
2011
- 2011-01-24 CN CN201810431471.6A patent/CN108383789A/zh active Pending
- 2011-01-24 AU AU2011209286A patent/AU2011209286B2/en not_active Ceased
- 2011-01-24 KR KR1020177036287A patent/KR101906791B1/ko active IP Right Grant
- 2011-01-24 MX MX2012008361A patent/MX353000B/es active IP Right Grant
- 2011-01-24 PL PL11701796T patent/PL2528901T3/pl unknown
- 2011-01-24 RS RS20150539A patent/RS54176B1/en unknown
- 2011-01-24 CN CN201510197776.1A patent/CN104829535A/zh active Pending
- 2011-01-24 AP AP2012006313A patent/AP3360A/xx active
- 2011-01-24 PE PE2012001022A patent/PE20121519A1/es active IP Right Grant
- 2011-01-24 CN CN201180016294.1A patent/CN102884051B/zh not_active Expired - Fee Related
- 2011-01-24 SG SG2012054599A patent/SG182684A1/en unknown
- 2011-01-24 GE GEAP201112849A patent/GEP20146177B/en unknown
- 2011-01-24 JP JP2012550408A patent/JP5658284B2/ja not_active Expired - Fee Related
- 2011-01-24 BR BR112012018695A patent/BR112012018695A2/pt not_active Application Discontinuation
- 2011-01-24 WO PCT/EP2011/050910 patent/WO2011092140A1/en active Application Filing
- 2011-01-24 MA MA35081A patent/MA33937B1/fr unknown
- 2011-01-24 CA CA2788224A patent/CA2788224C/en not_active Expired - Fee Related
- 2011-01-24 KR KR1020127019807A patent/KR101812000B1/ko active IP Right Grant
- 2011-01-24 UA UAA201210049A patent/UA110025C2/uk unknown
- 2011-01-24 DK DK11701796.2T patent/DK2528901T3/en active
- 2011-01-24 ES ES11701796.2T patent/ES2545865T3/es active Active
- 2011-01-24 HU HUE11701796A patent/HUE025318T2/en unknown
- 2011-01-24 SI SI201130571T patent/SI2528901T1/sl unknown
- 2011-01-24 PT PT117017962T patent/PT2528901E/pt unknown
- 2011-01-24 MY MYPI2012003353A patent/MY160036A/en unknown
- 2011-01-24 EA EA201201050A patent/EA022280B1/ru not_active IP Right Cessation
- 2011-01-24 EP EP11701796.2A patent/EP2528901B9/en active Active
- 2011-01-24 US US13/012,244 patent/US8791272B2/en not_active Expired - Fee Related
- 2011-01-24 NZ NZ600637A patent/NZ600637A/en not_active IP Right Cessation
- 2011-01-25 UY UY0001033201A patent/UY33201A/es not_active Application Discontinuation
- 2011-01-26 AR ARP110100257A patent/AR080032A1/es active IP Right Grant
- 2011-01-26 TW TW100102949A patent/TWI499416B/zh not_active IP Right Cessation
-
2012
- 2012-06-06 IL IL220208A patent/IL220208A/en not_active IP Right Cessation
- 2012-06-13 ZA ZA2012/04335A patent/ZA201204335B/en unknown
- 2012-07-06 CL CL2012001836A patent/CL2012001836A1/es unknown
- 2012-07-23 TN TNP2012000371A patent/TN2012000371A1/en unknown
- 2012-07-27 CO CO12126467A patent/CO6511272A2/es active IP Right Grant
-
2013
- 2013-03-19 HK HK13103377.2A patent/HK1176062A1/zh not_active IP Right Cessation
-
2015
- 2015-08-20 CY CY20151100728T patent/CY1116641T1/el unknown
- 2015-08-26 HR HRP20150898TT patent/HRP20150898T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY33201A (es) | Compuestos de pirazol como antagonistas de crth2. | |
ECSP12012174A (es) | Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a | |
CR20120594A (es) | Compuestos heteroarilo nitrogenados | |
CR11641A (es) | Derivados heterociclicos de urea y metodos de uso de los mismos-211 | |
UY31456A1 (es) | Derivados de 2-pirazinona como inhibidores de la elastasa de los neutrofilos | |
UY31189A1 (es) | Compuestos heterocíclicos | |
EA201290654A1 (ru) | Новые замещенные триазольные производные как модуляторы гамма-секретазы | |
UY32158A (es) | Derivados heterociclicos y metodos de uso de los mismos | |
PA8854101A1 (es) | Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa | |
ECSP088666A (es) | Derivados de las benzamidas y heteroarenos | |
CR20130309A (es) | Derivados de biciclo [3,2,1] octilamida y sus usos | |
UY32315A (es) | Compuestos de piperidina y usos de los mismo-596 | |
ECSP14013215A (es) | Compuestos novedosos | |
UY32736A (es) | Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas | |
CR11825A (es) | Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas | |
UY32674A (es) | Derivados heterociclicos de la urea y sus metodos de empleo | |
UY31865A (es) | Derivados de urea heterocíclicos y métodos para la utilización de los mismos | |
HN2011002578A (es) | Nuevos derivados de compuestos de [3,2-c]pirazol esteroidal con actividad clucocorticoide. | |
UY32856A (es) | Derivados heterocíclicos de urea y métodos de uso de los mismos | |
ECSP13012838A (es) | Nuevos compuestos de benzodioxol-piperazina | |
UY32694A (es) | Derivados heterocíclicos de urea y métodos de uso de los mismos | |
ECSP13012832A (es) | Compuestos de pirazol como antagonistas de crth2 | |
UY31000A1 (es) | Oxoisoxazoles como inhibidores de lipasas y fosfolipasas | |
UY32316A (es) | Derivados de piperidina utiles en el tratamiento de infecciones bacterianas | |
GT201300067A (es) | Nuevos derivados dihidrobenzoxatiazepinas. su procedimiento de preparacion y las composiciones farmaceuticas que los |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20210909 |